EyeControl Files IPO Prospectus: Revolutionizing Communication for ALS Patients with Affordable Eye-Controlled Smart Glasses

Stephen Hawking was born in Oxford, United Kingdom, on January 8, 1942. He is regarded as one of the most distinguished physicists since Newton and Einstein, and has been hailed as the “King of the Universe.” In 1963, Hawking was diagnosed with amyotrophic lateral sclerosis (ALS). As his condition progressively worsened, he could communicate with the outside world only through specialized glasses.

ALS, or amyotrophic lateral sclerosis, is a condition characterized by progressive muscle weakness and atrophy in the bulbar region (referring to muscles innervated by the medulla oblongata), limbs, trunk, chest, and abdomen, resulting from damage to both upper and lower motor neurons.

EyeControl smart glasses were designed to enable ALS patients to communicate simply and effortlessly.

Intel Manufacturing: The Tool That Enabled Hawking to Communicate with the World

As a communication device for ALS patients, EyeControl is by no means unique. As early as 2005, Intel designed and developed a corresponding communication system for Stephen Hawking, an ALS patient. Intel’s solution facilitated Hawking’s communication with the outside world through eye-tracking technology, predictive text input, and a speech synthesizer. However, such specialized services are evidently costly and unsuitable for ordinary ALS patients. Even if patients can afford the necessary communication equipment, its practical application remains inconvenient due to requirements such as fixed installation or the need for the patient to face the screen directly. For instance, improper use during car travel or other journeys could even pose life-threatening risks.

Implementation Path of EyeControl: Eye Movements – Data Information – Voice

EyeControl smart glasses enable patients to access high-quality services at a lower cost. The device comprises an infrared camera and a lightweight frame of eyeglasses attached to the camera, offering excellent portability.

During use, patients can wear these glasses to communicate freely without having to sit rigidly in front of a cold camera screen. Data is transmitted to a credit-card-sized computer, which identifies and analyzes the patient’s blinks and eye movements, converting them into audio signals representing meaningful information that are then played through a speaker.
Furthermore, it can transmit data to a smartphone via Bluetooth, and the paired app can also receive the simulated patient voice signals generated after identification, thereby enabling communication.

EyeControl smart glasses were launched by three co-founders, one of whom is an ALS patient. Additionally, the product’s applications include triggering alerts to call for assistance, selecting from predefined sentences (such as “I’m cold,” “My hand hurts,” or “I need to urinate”), and using simple sentences or words to simulate the messages patients wish to convey.

According to data from the official website of the ALS Association, the incidence rate of ALS is 2 per 100,000 people, which translates to an estimated global prevalence of approximately 120,000 individuals. In the United States alone, more than 5,600 new cases are diagnosed each year.

ALS inflicts immense suffering on patients, yet more than 70% of ALS patients worldwide cannot afford the corresponding communication devices (according to official data from EyeControl). This presents a market opportunity for EyeControl, which is dedicated to making such devices simple and portable. However, the price of EyeControl’s smart glasses has not yet been announced.